Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Application of permeability-limited physiologically-based pharmacokinetic models: part I-digoxin pharmacokinetics incorporating P-glycoprotein-mediated efflux.

Neuhoff S, Yeo KR, Barter Z, Jamei M, Turner DB, Rostami-Hodjegan A.

J Pharm Sci. 2013 Sep;102(9):3145-60. doi: 10.1002/jps.23594. Epub 2013 May 22.

PMID:
23703021
2.

Application of permeability-limited physiologically-based pharmacokinetic models: part II - prediction of P-glycoprotein mediated drug-drug interactions with digoxin.

Neuhoff S, Yeo KR, Barter Z, Jamei M, Turner DB, Rostami-Hodjegan A.

J Pharm Sci. 2013 Sep;102(9):3161-73. doi: 10.1002/jps.23607. Epub 2013 May 19.

PMID:
23686764
3.

Predicting drug-drug interactions: application of physiologically based pharmacokinetic models under a systems biology approach.

Yeo KR, Jamei M, Rostami-Hodjegan A.

Expert Rev Clin Pharmacol. 2013 Mar;6(2):143-57. doi: 10.1586/ecp.13.4. Review.

PMID:
23473592
4.

Application of in vitro-in vivo extrapolation (IVIVE) and physiologically based pharmacokinetic (PBPK) modelling to investigate the impact of the CYP2C8 polymorphism on rosiglitazone exposure.

Yeo KR, Kenny JR, Rostami-Hodjegan A.

Eur J Clin Pharmacol. 2013 Jun;69(6):1311-20. doi: 10.1007/s00228-012-1467-3. Epub 2013 Jan 11.

PMID:
23307233
5.
6.

Sources of interindividual variability in IVIVE of clearance: an investigation into the prediction of benzodiazepine clearance using a mechanistic population-based pharmacokinetic model.

Cubitt HE, Yeo KR, Howgate EM, Rostami-Hodjegan A, Barter ZE.

Xenobiotica. 2011 Aug;41(8):623-38. doi: 10.3109/00498254.2011.560294. Epub 2011 Mar 24.

PMID:
21434772
7.

Determination of a quantitative relationship between hepatic CYP3A5*1/*3 and CYP3A4 expression for use in the prediction of metabolic clearance in virtual populations.

Barter ZE, Perrett HF, Yeo KR, Allorge D, Lennard MS, Rostami-Hodjegan A.

Biopharm Drug Dispos. 2010 Nov;31(8-9):516-32. doi: 10.1002/bdd.732.

PMID:
21104927
8.

Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions.

Yang J, Liao M, Shou M, Jamei M, Yeo KR, Tucker GT, Rostami-Hodjegan A.

Curr Drug Metab. 2008 Jun;9(5):384-94. Review.

PMID:
18537575
9.

Prediction of intestinal first-pass drug metabolism.

Yang J, Jamei M, Yeo KR, Tucker GT, Rostami-Hodjegan A.

Curr Drug Metab. 2007 Oct;8(7):676-84. Review.

PMID:
17979655
10.

Theoretical assessment of a new experimental protocol for determining kinetic values describing mechanism (time)-based enzyme inhibition.

Yang J, Jamei M, Yeo KR, Tucker GT, Rostami-Hodjegan A.

Eur J Pharm Sci. 2007 Jul;31(3-4):232-41. Epub 2007 Apr 25.

PMID:
17512176
11.

Misuse of the well-stirred model of hepatic drug clearance.

Yang J, Jamei M, Yeo KR, Rostami-Hodjegan A, Tucker GT.

Drug Metab Dispos. 2007 Mar;35(3):501-2. No abstract available.

PMID:
17325025
12.

The effect of chronic tobacco smoking on arterial stiffness.

Rehill N, Beck CR, Yeo KR, Yeo WW.

Br J Clin Pharmacol. 2006 Jun;61(6):767-73.

13.

Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA.

Yang J, Jamei M, Heydari A, Yeo KR, de la Torre R, Farré M, Tucker GT, Rostami-Hodjegan A.

J Psychopharmacol. 2006 Nov;20(6):842-9. Epub 2006 May 19.

PMID:
16714321
14.

Kinetic values for mechanism-based enzyme inhibition: assessing the bias introduced by the conventional experimental protocol.

Yang J, Jamei M, Yeo KR, Tucker GT, Rostami-Hodjegan A.

Eur J Pharm Sci. 2005 Nov;26(3-4):334-40.

PMID:
16137870
15.

Mechanism-based inactivation of CYP2D6 by methylenedioxymethamphetamine.

Heydari A, Yeo KR, Lennard MS, Ellis SW, Tucker GT, Rostami-Hodjegan A.

Drug Metab Dispos. 2004 Nov;32(11):1213-7. Epub 2004 Aug 24.

PMID:
15328252
16.

Coronary risk versus cardiovascular risk for treatment decisions in mild hypertension.

Yeo WW, Yeo KR.

J Cardiovasc Risk. 2002 Oct;9(5):275-80.

PMID:
12394321
17.

Should we treat high-normal blood pressure?

Yeo KR, Yeo WW.

J Hypertens. 2002 Oct;20(10):2057-62.

PMID:
12359985
18.

Predicting CHD risk in patients with diabetes mellitus.

Yeo WW, Yeo KR.

Diabet Med. 2001 May;18(5):341-4. No abstract available.

PMID:
11472442
19.
20.

Enhanced cholesterol reduction by simvastatin in diltiazem-treated patients.

Yeo KR, Yeo WW, Wallis EJ, Ramsay LE.

Br J Clin Pharmacol. 1999 Oct;48(4):610-5.

Supplemental Content

Support Center